{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:55:58Z","timestamp":1773662158759,"version":"3.50.1"},"reference-count":23,"publisher":"American Association for Cancer Research (AACR)","issue":"20","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Purpose: Prostate cancer is a highly prevalent malignancy and constitutes a major cause of cancer-related morbidity and mortality. Owing to the limitations of current clinical, serologic, and pathologic parameters in predicting disease progression, we sought to investigate the prognostic value of promoter methylation of a small panel of genes by quantitative methylation-specific PCR (QMSP) in prostate biopsies.<\/jats:p>\n               <jats:p>Experimental Design: Promoter methylation levels of APC, CCND2, GSTP1, RARB2, and RASSF1A were determined by QMSP in a prospective series of 83 prostate cancer patients submitted to sextant biopsy. Clinicopathologic data [age, serum prostate-specific antigen (PSA), stage, and Gleason score] and time to progression and\/or death from prostate cancer were correlated with methylation findings. Log-rank test and Cox regression model were used to identify which epigenetic markers were independent predictors of prognosis.<\/jats:p>\n               <jats:p>Results: At a median follow-up time of 45 months, 15 (18%) patients died from prostate cancer, and 37 (45%) patients had recurrent disease. In univariate analysis, stage and hypermethylation of APC were significantly associated with worse disease\u2013specific survival, whereas stage, Gleason score, high diagnostic serum PSA levels, and hypermethylation of APC, GSTP1, and RASSF1A were significantly associated with poor disease-free survival. However, in the final multivariate analysis, only clinical stage and high methylation of APC were significantly and independently associated with unfavorable prognosis, i.e., decreased disease-free and disease-specific survival.<\/jats:p>\n               <jats:p>Conclusions: High-level APC promoter methylation is an independent predictor of poor prognosis in prostate biopsy samples and might provide relevant prognostic information for patient management.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-07-1042","type":"journal-article","created":{"date-parts":[[2007,10,18]],"date-time":"2007-10-18T18:23:25Z","timestamp":1192731805000},"page":"6122-6129","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["High Promoter Methylation Levels of <i>APC<\/i> Predict Poor Prognosis in Sextant Biopsies from Prostate Cancer Patients"],"prefix":"10.1158","volume":"13","author":[{"given":"Rui","family":"Henrique","sequence":"first","affiliation":[{"name":"1Pathology, Departments of"},{"name":"5Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto, and"}]},{"given":"Franclim R.","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"2Genetics,"}]},{"given":"Daniel","family":"Fonseca","sequence":"additional","affiliation":[{"name":"3Radiology, and"}]},{"given":"Mohammad O.","family":"Hoque","sequence":"additional","affiliation":[{"name":"7Division of Head and Neck Cancer Research, Department of Otolaryngology, Johns Hopkins University, Baltimore, Maryland"}]},{"given":"Andre\u0301 L.","family":"Carvalho","sequence":"additional","affiliation":[{"name":"7Division of Head and Neck Cancer Research, Department of Otolaryngology, Johns Hopkins University, Baltimore, Maryland"}]},{"given":"Vera L.","family":"Costa","sequence":"additional","affiliation":[{"name":"2Genetics,"}]},{"given":"Mafalda","family":"Pinto","sequence":"additional","affiliation":[{"name":"2Genetics,"}]},{"given":"Jorge","family":"Oliveira","sequence":"additional","affiliation":[{"name":"4Urology, Portuguese Oncology Institute\u2013Porto,"}]},{"given":"Manuel R.","family":"Teixeira","sequence":"additional","affiliation":[{"name":"2Genetics,"},{"name":"5Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto, and"}]},{"given":"David","family":"Sidransky","sequence":"additional","affiliation":[{"name":"7Division of Head and Neck Cancer Research, Department of Otolaryngology, Johns Hopkins University, Baltimore, Maryland"}]},{"given":"Carmen","family":"Jero\u0301nimo","sequence":"additional","affiliation":[{"name":"2Genetics,"},{"name":"5Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto, and"},{"name":"6School of Health Sciences, Fernando Pessoa University, Porto, Portugal; and"}]}],"member":"1086","published-online":{"date-parts":[[2007,10,18]]},"reference":[{"key":"2022061105362026400_B1","doi-asserted-by":"crossref","unstructured":"Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin\u20082006;56:106\u201330.","DOI":"10.3322\/canjclin.56.2.106"},{"key":"2022061105362026400_B2","doi-asserted-by":"crossref","unstructured":"Stamey TA. Making the most out of six systematic sextant biopsies. Urology\u20081995;45:2\u201312.","DOI":"10.1016\/S0090-4295(95)96168-2"},{"key":"2022061105362026400_B3","doi-asserted-by":"crossref","unstructured":"King CR, Long JP. Prostate biopsy grading errors: a sampling problem? Int J Cancer\u20082000;90:326\u201330.","DOI":"10.1002\/1097-0215(20001220)90:6<326::AID-IJC3>3.0.CO;2-J"},{"key":"2022061105362026400_B4","doi-asserted-by":"crossref","unstructured":"Allsbrook WC, Jr., Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI. Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol\u20082001;32:81\u20138.","DOI":"10.1053\/hupa.2001.21135"},{"key":"2022061105362026400_B5","doi-asserted-by":"crossref","unstructured":"Jero\u0301nimo C, Henrique R, Sidransky D. Uses of DNA methylation in cancer diagnosis and risk assessment. In: Esteller M, editor. DNA methylation. Approaches, methods and applications. CRC Press: Boca Raton; 2004. p. 11\u201326.","DOI":"10.1201\/9780203487013.ch2"},{"key":"2022061105362026400_B6","doi-asserted-by":"crossref","unstructured":"Costa VL, Henrique R, Jero\u0301nimo C. Epigenetic markers for molecular detection of prostate cancer. Dis Markers\u20082007;23:31\u201341.","DOI":"10.1155\/2007\/356742"},{"key":"2022061105362026400_B7","doi-asserted-by":"crossref","unstructured":"Bastian PJ, Palapattu GS, Lin X, et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res\u20082005;11:4037\u201343.","DOI":"10.1158\/1078-0432.CCR-04-2446"},{"key":"2022061105362026400_B8","doi-asserted-by":"crossref","unstructured":"Rosenbaum E, Hoque MO, Cohen Y, et al. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res\u20082005;11:8321\u20135.","DOI":"10.1158\/1078-0432.CCR-05-1183"},{"key":"2022061105362026400_B9","doi-asserted-by":"crossref","unstructured":"Ribeiro FR, Jero\u0301nimo C, Henrique R, et al. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Clin Cancer Res\u20082006;12:3961\u201370.","DOI":"10.1158\/1078-0432.CCR-05-1977"},{"key":"2022061105362026400_B10","unstructured":"Cairns P, Esteller M, Herman JG, et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res\u20082001;7:2727\u201330."},{"key":"2022061105362026400_B11","doi-asserted-by":"crossref","unstructured":"Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol\u20081974;111:58\u201364.","DOI":"10.1016\/S0022-5347(17)59889-4"},{"key":"2022061105362026400_B12","doi-asserted-by":"crossref","unstructured":"Hermanek P, Hutter RVP, Sobin LH, Wagner G, Wittekind C. Prostate. In: Hermanek P, Hutter RVP, Sobin LH, Wagner G, Wittekind C, editors. Illustrated guide to the TNM\/pTNM classification of malignant tumors. Springer-Verlag: Heidelberg; 1997. p. 278\u201380.","DOI":"10.1007\/978-3-662-03432-3"},{"key":"2022061105362026400_B13","doi-asserted-by":"crossref","unstructured":"Jero\u0301nimo C, Henrique R, Hoque MO, et al. Quantitative RAR\u03b22 hypermethylation: a promising prostate cancer marker. Clin Cancer Res\u20082004;10:4010\u20134.","DOI":"10.1158\/1078-0432.CCR-03-0643"},{"key":"2022061105362026400_B14","doi-asserted-by":"crossref","unstructured":"Jero\u0301nimo C, Usadel H, Henrique R, et al. Quantitation of GSTP1 hypermethylation distinguishes between non-neoplastic prostatic tissue and organ confined prostate adenocarcinoma. J Natl Cancer Inst\u20082001;93:1747\u201352.","DOI":"10.1093\/jnci\/93.22.1747"},{"key":"2022061105362026400_B15","unstructured":"Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res\u20082002;62:371\u20135."},{"key":"2022061105362026400_B16","doi-asserted-by":"crossref","unstructured":"Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol\u20082002;160:605\u201312.","DOI":"10.1016\/S0002-9440(10)64880-8"},{"key":"2022061105362026400_B17","doi-asserted-by":"crossref","unstructured":"Henrique R, Costa VL, Cerveira N, et al. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med\u20082006;84:911\u20138.","DOI":"10.1007\/s00109-006-0099-4"},{"key":"2022061105362026400_B18","doi-asserted-by":"crossref","unstructured":"Jero\u0301nimo C, Henrique R, Hoque MO, et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res\u20082004;10:8472\u20138.","DOI":"10.1158\/1078-0432.CCR-04-0894"},{"key":"2022061105362026400_B19","doi-asserted-by":"crossref","unstructured":"Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol\u20082004;17:292\u2013306.","DOI":"10.1038\/modpathol.3800054"},{"key":"2022061105362026400_B20","doi-asserted-by":"crossref","unstructured":"Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res\u20082004;64:1975\u201386.","DOI":"10.1158\/0008-5472.CAN-03-3972"},{"key":"2022061105362026400_B21","doi-asserted-by":"crossref","unstructured":"Tokumaru Y, Harden SV, Sun DI, Yamashita K, Epstein JI, Sidransky D. Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res\u20082004;10:5518\u201322.","DOI":"10.1158\/1078-0432.CCR-04-0108"},{"key":"2022061105362026400_B22","doi-asserted-by":"crossref","unstructured":"Bastian PJ, Ellinger J, Wellmann A, et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res\u20082005;11:4097\u2013106.","DOI":"10.1158\/1078-0432.CCR-04-1832"},{"key":"2022061105362026400_B23","doi-asserted-by":"crossref","unstructured":"Ribeiro FR, Henrique R, Martins AT, Jero\u0301nimo C, Teixeira MR. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients. Eur Urol\u20082007;52:116\u201325.","DOI":"10.1016\/j.eururo.2006.09.018"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/13\/20\/6122\/1971627\/6122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/13\/20\/6122\/1971627\/6122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T20:39:37Z","timestamp":1654979977000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/13\/20\/6122\/194749\/High-Promoter-Methylation-Levels-of-APC-Predict"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,15]]},"references-count":23,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2007,10,18]]},"published-print":{"date-parts":[[2007,10,15]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-07-1042","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,15]]}}}